U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced a bold plan to identify the cause of autism by September 2025. Speaking at a cabinet meeting with President Donald Trump, Kennedy declared a global research initiative involving hundreds of scientists to determine the source of rising autism rates, which reached 1 in 36 children by 2020, according to the CDC.
“We’ll know by September what has caused the autism epidemic and how to eliminate those exposures,” Kennedy said, hinting at environmental and artificial factors. The initiative is part of Trump’s broader “Make America Healthy Again” Commission, which is also reviewing rising childhood conditions like asthma and ADHD.
The autism community, however, responded with skepticism. Kristyn Roth of the Autism Society of America criticized the deadline and the framing of autism as an “epidemic,” warning it promotes fear and stigmatization. Experts caution that increased diagnoses are largely due to expanded diagnostic criteria and awareness, not an unknown epidemic.
Kennedy, known for promoting a disproven link between vaccines and autism, confirmed vaccines will be reviewed, along with potential environmental and lifestyle triggers. Meanwhile, a recent study has strengthened ties between prenatal diabetes and autism risk.
Controversy deepened after reports surfaced of David Geier—previously fined for unlicensed medical practices—being hired to investigate vaccine links. Lawmakers and advocacy groups fear the spread of misinformation under Kennedy’s leadership.
The National Institutes of Health and the CDC, both under Kennedy’s purview, are planning multimillion-dollar research efforts into autism causes, including vaccine-related studies. Critics argue the push may politicize science and mislead the public.
Despite widespread concern, Kennedy remains firm: “There will be no bigger news than finding the cause of autism.” Whether science can meet his deadline remains uncertain.


Ohio Man Indicted for Alleged Threat Against Vice President JD Vance, Faces Additional Federal Charges
U.S. to Begin Paying UN Dues as Financial Crisis Spurs Push for Reforms
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Tabletop particle accelerator could transform medicine and materials science
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out
US Pushes Ukraine-Russia Peace Talks Before Summer Amid Escalating Attacks
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Neuralink Expands Brain Implant Trials with 12 Global Patients
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 



